Form 4: Black Diamond Therapeutics Director Acquires Stock Options

Director Samarth Kulkarni of Black Diamond Therapeutics, Inc. acquired 40,000 stock options with an exercise price of $1.71.

Summary

• Samarth Kulkarni, a Director at Black Diamond Therapeutics, Inc. (BDTX), acquired 40,000 stock options on June 26, 2026.
• The options have an exercise price of $1.71 per share.
• These options are exercisable upon the earlier of June 26, 2027, or the Issuer's next annual meeting of stockholders, contingent on continued service.
• Following the transaction, Kulkarni beneficially owns 40,000 shares of common stock through these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a routine event and does not inherently signal positive or negative company performance.

Positives

• Director Kulkarni's acquisition of stock options indicates a commitment to the company's future performance.
• The vesting schedule tied to continued service aligns management incentives with long-term shareholder value.

Risks

• The value of the acquired stock options is directly tied to the future stock price performance of Black Diamond Therapeutics, which carries inherent market risks.
• Continued service is a condition for vesting, meaning any departure from the company before the vesting date would result in forfeiture of the options.

Future Outlook

The future outlook for the acquired stock options is dependent on the company's stock performance and the reporting person's continued service, with full exercisability expected by June 26, 2027, or the next annual meeting.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as a long-term incentive to align executive interests with shareholder value and encourage sustained performance.

Stakeholder Impact

• Shareholders: The issuance of stock options to a director aligns their interests with long-term stock performance, potentially benefiting shareholders if the company succeeds.
• Employees: This type of compensation for directors is standard and does not directly impact most employees, though overall company success driven by management can have indirect effects.

Next Steps

• Director Kulkarni will continue to serve the company to meet vesting requirements for the stock options.
• The stock options will become exercisable on or before June 26, 2027, or the company's next annual meeting.
• The options expire on June 25, 2036.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Form 4, Stock Options, Director, Beneficial Ownership, Insider Trading, SEC Filing